The predictive value of E2F7 in immunotherapy efficacy for lung adenocarcinoma: An observational study

Heran Cui,Hui Li,Jingjing Liu,Peiyan Zhao,Yan Liu,Rui Zhong,Rixin Li,Ying Cheng

DOI: https://doi.org/10.1097/md.0000000000038574

IF: 1.6

2024-06-23

Medicine

Abstract:Lung cancer is the most common malignant tumor, which is the main cause of cancer-related death. [ 1 ] Lung adenocarcinoma (LUAD) is the most common lung cancer pathology. Due to early asymptomatic or mild symptoms, the LUAD diagnosis is often in the advanced stage, and the 5-year overall survival rate of advanced LUAD patients is <20%. [ 2 ] Recently, the immunotherapy clinical application changed the treatment mode of advanced LUAD, significantly improving the survival rate and life quality of LUAD patients. Immunotherapy is a treatment method that reactivates the immune system to eliminate tumor cells by blocking immune checkpoints such as programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). It exhibits an effective and long-lasting anti-tumor response in LUAD patients. [ 3–5 ] However, only a small portion of LUAD patients benefitted from immune checkpoint inhibitor therapy, and only about 20% overall response rate was observed in unscreened immunotherapy patients. [ 6 ] Currently, several biomarkers were being used to predict immune therapy responses, including tumor mutation burden (TMB) and PD-L1 expression. [ 7 ] Unfortunately, studies have reported that patients with relatively high levels of TMB exhibited different immune therapy responses. [ 8 ] The internal heterogeneity of PD-L1 expression limited its value in predicting immune therapy responses, [ 9–11 ] indicating that these biomarkers cannot fully reflect the efficacy of immune therapy and there was an urgent need to develop new a biomarker for predicting immune therapy responses.

medicine, general & internal